A retrospective comparison of CD19 single and CD19/CD22 bispecific targeted chimeric antigen receptor T cell therapy in patients with relapsed/refractory acute lymphoblastic leukemia

被引：0
|
作者：
Yiyun Wang
Yingying Yang
Ruimin Hong
Houli Zhao
Guoqing Wei
Wenjun Wu
Huijun Xu
Jiazhen Cui
Yanlei Zhang
Alex H. Chang
Yongxian Hu
He Huang
机构：
[1] Zhejiang University School of Medicine,Bone Marrow Transplantation Center, The First Affiliated Hospital
[2] Zhejiang University,Institute of Hematology
[3] Zhejiang Province Engineering Laboratory for Stem Cell and Immunity Therapy,Zhejiang Laboratory for Systems & Precision Medicine
[4] Zhejiang University Medical Center,undefined
[5] Shanghai YaKe Biotechnology Ltd,undefined
来源：
Blood Cancer Journal | / 10卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] A Feasibility and Safety Study of CD19 and CD22 Chimeric Antigen Receptors-Modified T Cell Cocktail for Therapy of B Cell Acute Lymphoblastic Leukemia
    Yang, Junfang
    Li, Jianqiang
    Zhang, Xian
    Lv, Fanyong
    Guo, Xiaoling
    Wang, Qinglong
    Wang, Lin
    Chen, Dandan
    Zhou, Xiaosu
    Ren, Jinhai
    Lu, Peihua
    BLOOD, 2018, 132
  • [22] Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?
    Liu, Sining
    Zhang, Xinyue
    Dai, Haiping
    Cui, Wei
    Yin, Jia
    Li, Zheng
    Yang, Xiao
    Yang, Chunxiu
    Xue, Shengli
    Qiu, Huiying
    Miao, Miao
    Chen, Suning
    Jin, Zhengming
    Fu, Chengcheng
    Li, Caixia
    Sun, Aining
    Han, Yue
    Wang, Ying
    Yu, Lei
    Wu, Depei
    Cui, Qingya
    Tang, Xiaowen
    BLOOD CANCER JOURNAL, 2023, 13 (01)
  • [23] CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Aggressive B-Cell Lymphoma: a Safety and Efficacy Study
    Hu, Yongxian
    Zhang, Yanlei
    Zhao, Houli
    Wang, Yiyun
    Nagler, Arnon
    Chang, Alex Hong
    Huang, He
    BLOOD, 2020, 136
  • [24] Tandem CD19/CD22 Dual Targets CAR-T Cells Therapy Obtains Superior CR Rate Than Single CD19 CAR-T Cells Infusion As Well As Sequential CD19 and CD22 CAR-T Cells Infusion for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Patients
    Liu, Sining
    Zhang, Xinyue
    Dai, Haiping
    Cui, Qingya
    Cui, Wei
    Yin, Jia
    Li, Zheng
    Xue, Shengli
    Yang, Chunxiu
    Yang, Xiao
    Qiu, Huiying
    Miao, Miao
    Chen, Suning
    Jin, Zhengming
    Fu, Chengcheng
    Li, Caixia
    Sun, Aining
    Han, Yue
    Wang, Ying
    Yu, Lei
    Wu, Depei
    Tang, Xiaowen
    BLOOD, 2021, 138
  • [25] Efficacy and safety of chimeric antigen receptor T-cell therapy targeting CD19/CD22 in refractory/relapsed transformed aggressive B-cell lymphoma
    Xu, Hao
    Lv, Qiuxia
    Huang, Liang
    Cao, Wenyue
    Wang, Jue
    Meng, Fankai
    Li, Chunrui
    Zheng, Miao
    Chen, Liting
    Mu, Ketao
    Cheng, Jiali
    Zhu, Li
    Zhou, Jianfeng
    Zhang, Yicheng
    Wang, Na
    Cao, Yang
    CYTOTHERAPY, 2023, 25 (02) : 185 - 191
  • [26] Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia (vol 13, 30, 2020)
    Dai, Hanren
    Wu, Zhiqiang
    Jia, Hejin
    Tong, Chuan
    Guo, Yelei
    Ti, Dongdong
    Han, Xiao
    Liu, Yang
    Zhang, Wenying
    Wang, Chunmeng
    Zhang, Yajing
    Chen, Meixia
    Yang, Qingming
    Wang, Yao
    Han, Weidong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [27] CD22 Gating for Flow Cytometric Analysis in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia after CD19 CAR-T Therapy
    Yu, Xinjian
    Li, Pan
    Feng, Heyuan
    Kang, Jian
    Zheng, Xichang
    Zhang, Yunmei
    Yang, Wenhong
    Wu, Tong
    Liu, Shuangyou
    BLOOD, 2020, 136
  • [28] Heterogeneity of surface CD19 and CD22 expression in B lymphoblastic leukemia
    Rosenthal, Jaclyn
    Naqvi, Ammar S.
    Luo, Minjie
    Wertheim, Gerald
    Paessler, Michele
    Thomas-Tikhonenko, Andrei
    Rheingold, Susan R.
    Pillai, Vinodh
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (11) : E352 - E355
  • [29] Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract
    Zeng, Chen
    Cheng, Jiali
    Li, Tongjuan
    Huang, Jin
    Li, Chunrui
    Jiang, Lijun
    Wang, Jue
    Chen, Liting
    Mao, Xia
    Zhu, Li
    Lou, Yaoyao
    Zhou, Jianfeng
    Zhou, Xiaoxi
    CYTOTHERAPY, 2020, 22 (03) : 166 - 171
  • [30] Double CD19/CD22 Chimeric Antigen Receptor-Modified T Cells for the Treatment of Stage IV Relapsed and Refractory Follicular Lymphoma
    Lai, Xun
    Gu, Xuezhong
    Tsao, Shih-Ting
    Zhang, Qin
    Liu, Yu-Chen
    Jiang Yaxian
    Yan, Li
    Chun, Jun
    Zhang, Rui
    Du, Yunyun
    Gao, Xiaoli
    Yang, Yingyu
    Qiu, Xiaolian
    Fang, Mingjing
    Wei, Song
    Chang, Lung-Ji
    BLOOD, 2017, 130
12345